Voya Investment Management LLC Sells 30,462 Shares of Neurocrine Biosciences, Inc. $NBIX

Voya Investment Management LLC trimmed its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 25.0% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 91,278 shares of the company’s stock after selling 30,462 shares during the quarter. Voya Investment Management LLC’s holdings in Neurocrine Biosciences were worth $12,814,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Dodge & Cox boosted its position in Neurocrine Biosciences by 0.6% during the second quarter. Dodge & Cox now owns 5,566,814 shares of the company’s stock valued at $699,693,000 after buying an additional 32,190 shares during the period. JPMorgan Chase & Co. boosted its holdings in Neurocrine Biosciences by 59.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,261,747 shares of the company’s stock valued at $535,659,000 after acquiring an additional 1,590,749 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Neurocrine Biosciences by 3.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,539,601 shares of the company’s stock valued at $170,281,000 after acquiring an additional 49,088 shares during the period. AQR Capital Management LLC grew its position in Neurocrine Biosciences by 40.5% during the 2nd quarter. AQR Capital Management LLC now owns 1,510,015 shares of the company’s stock worth $189,794,000 after acquiring an additional 435,385 shares during the last quarter. Finally, Braidwell LP lifted its position in Neurocrine Biosciences by 32.2% in the first quarter. Braidwell LP now owns 1,191,925 shares of the company’s stock valued at $131,827,000 after purchasing an additional 290,135 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on NBIX. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Wednesday, October 8th. UBS Group raised their price target on shares of Neurocrine Biosciences from $188.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. JPMorgan Chase & Co. increased their target price on shares of Neurocrine Biosciences from $171.00 to $179.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Stifel Nicolaus boosted their price target on Neurocrine Biosciences from $183.00 to $188.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, Wedbush reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $175.25.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ:NBIX opened at $147.53 on Tuesday. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $160.18. The firm has a market capitalization of $14.71 billion, a P/E ratio of 35.29, a P/E/G ratio of 0.95 and a beta of 0.27. The stock has a 50 day moving average price of $146.37 and a 200-day moving average price of $138.28.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.59. The business had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The firm’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.81 earnings per share. On average, equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 300 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $141.97, for a total value of $42,591.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares in the company, valued at approximately $19,933,581.79. This trade represents a 0.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director William H. Rastetter sold 18,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total transaction of $2,732,760.00. Following the completion of the sale, the director owned 40,360 shares of the company’s stock, valued at $6,127,455.20. This represents a 30.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 43,866 shares of company stock valued at $6,570,237 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.